BioXcel Therapeutics CFO sells over $2.8k in company stock

In a recent move that has caught the attention of investors, Richard I. Steinhart, the Chief Financial Officer of BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a pharmaceutical company, has sold a portion of his holdings in the company. The transaction, which took place on April 4, 2024, involved the sale of 1,069 shares at a weighted average price ranging from $2.62 to $2.665, resulting in a total transaction value of approximately $2,816.

The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell company stocks. The plan was adopted by Steinhart on December 14, 2023, providing a systematic approach to the divestiture of his shares.

Prior to the sale, the CFO also acquired shares through the vesting of restricted stock units (RSUs). On March 14 and 15, Steinhart acquired 521 and 2,250 RSUs, respectively. Each RSU represents a contingent right to receive one share of BioXcel Therapeutics' common stock. These transactions did not involve any monetary exchange as they pertain to the vesting schedule of previously granted equity awards. Following the vesting and subsequent sale, Steinhart's ownership in the company stands at 6,750 shares of common stock.

The transactions come at a time when BioXcel Therapeutics continues to navigate the pharmaceutical industry, focusing on the development of innovative drug therapies. Investors often monitor insider transactions as they may provide insights into the executive's view of the company's prospects.

BioXcel Therapeutics, based in New Haven, Connecticut, is known for its work in the pharmaceutical preparations sector and operates under the organization name 03 Life Sciences. The company's common stock trades on the NASDAQ under the ticker symbol BTAI.

As with any insider transactions, the details of the sales and acquisitions are publicly disclosed to ensure transparency and maintain fair trading practices in accordance with securities regulations.

Amidst the insider trading activities by BioXcel Therapeutics' CFO, Richard I. Steinhart, investors are keen to understand the company's financial health and future prospects. According to the latest data from InvestingPro, BioXcel Therapeutics has a market capitalization of $80.42 million. The company's aggressive sales growth is evident, with a remarkable 268.0% increase in revenue over the last twelve months as of Q4 2023. Despite this surge, the company maintains a low gross profit margin of 8.7%, reflecting challenges in cost management and profitability.

One of the InvestingPro Tips highlights that analysts do not expect the company to be profitable this year, which aligns with the reported operating income margin of -12146.3% for the same period. This metric underscores the significant expenses incurred relative to the revenue generated. Furthermore, the stock's performance has been underwhelming, with a 1-year price total return of -84.78%, indicating a substantial decline in investor confidence.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

For those investors looking for more in-depth analysis, InvestingPro offers additional insights, including 10 more InvestingPro Tips for BioXcel Therapeutics. These tips provide a comprehensive look at the company's financial metrics and market performance, which could be invaluable for making informed investment decisions. To gain access to these insights, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.